{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents&page=3", "query": { "condition": "Antineoplastic Agents", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 256, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T05:01:47.098Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05288166", "title": "A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms", "Neoplasm Metastasis", "Urogenital Neoplasms", "Physiological Effects of Drugs", "Antineoplastic Agents", "Antineoplastic Agents, Hormonal", "Androgens", "Hormones", "Hormones, Hormone Substitutes, and Hormone Antagonists", "Abiraterone Acetate", "Steroid Synthesis Inhibitors", "Cytochrome P-450", "Enzyme Inhibitors", "Prednisone", "Prednisolone", "Cyclin-Dependent Kinase 4", "Cyclin-Dependent Kinase 6" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone or Prednisolone", "type": "DRUG" }, { "name": "Placebo for Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 925, "start_date": "2022-04-14", "completion_date": "2027-10", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 63, "location_summary": "Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more", "locations": [ { "city": "Prescott", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05288166" }, { "nct_id": "NCT04784715", "title": "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer; HER2-positive; Metastatic" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1157, "start_date": "2021-04-26", "completion_date": "2029-12-30", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 30, "location_summary": "Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Longmont", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04784715" }, { "nct_id": "NCT04704921", "title": "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "AMD", "nAMD", "Wet Age-related Macular Degeneration", "wAMD", "Wet AMD", "CNV", "Neovascular AMD", "Neovascular Age-related Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "ABBV-RGX-314", "type": "GENETIC" }, { "name": "Ranibizumab (LUCENTIS®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 671, "start_date": "2020-12-29", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 89, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704921" }, { "nct_id": "NCT07738939", "title": "IKS04 Regimen in Advanced Solid Tumors That Express CA242", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Gastro Esophageal Junctional Cancer", "Gastric Cancer (GC)", "GEJ Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)", "Gall Bladder Cancer", "Cholangiocarcinoma" ], "interventions": [ { "name": "IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Iksuda Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-11", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07738939" }, { "nct_id": "NCT06130553", "title": "A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors That Are MTAP Deficient" ], "interventions": [ { "name": "AZD3470", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 334, "start_date": "2024-01-18", "completion_date": "2028-12-04", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 8, "location_summary": "San Francisco, California • West Hollywood, California • New Haven, Connecticut + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06130553" }, { "nct_id": "NCT07123454", "title": "A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "AZD4512", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2025-09-24", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 8, "location_summary": "Irvine, California • Jacksonville, Florida • Rochester, Minnesota + 4 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07123454" }, { "nct_id": "NCT04595851", "title": "Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Multiple Chronic Conditions" ], "interventions": [ { "name": "Patient Reported Outcome Measure (PROM)", "type": "OTHER" }, { "name": "Comprehensive Medication Review (CMR)", "type": "OTHER" }, { "name": "Communications between oncology and primary care pharmacists", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-03-26", "completion_date": "2022-07-14", "has_results": false, "last_update_posted_date": "2022-11-22", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04595851" }, { "nct_id": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors, Adult" ], "interventions": [ { "name": "STX-478", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2023-04-17", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 28, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768139" }, { "nct_id": "NCT04964934", "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ER-Positive HER2-Negative Breast Cancer" ], "interventions": [ { "name": "AZD9833", "type": "DRUG" }, { "name": "AZD9833 Placebo", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Anastrozole placebo", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Letrozole placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) agonist", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 315, "start_date": "2021-06-30", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 64, "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04964934" }, { "nct_id": "NCT01754987", "title": "A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Advanced Liver Cancer" ], "interventions": [ { "name": "Ascorbic Acid + Sorafenib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2012-09", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-10-04T05:01:47.098Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01754987" } ] }